Combination Therapy with Interferon Alfa-2b and Hydroxyurea during the Accelerated Phase of Chronic Myelogenous Leukemia

Acta Haematologica

Volumn 95, Issue 2, 1996, Pages 117-121

  Bourantas, K L ^a   Syrou, M ^b   Tsiara, S ^a   Danella, M ^a   Konstantinides, P ^a  

^a First Propaedeutic Department of Internal Medicine   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Accelerated phase; Chronic myelogenous leukemia; Hydroxyurea; Interferon alfa 2b

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA2B INTERFERON; HYDROXYUREA;

ADULT; AGED; ARTICLE; BASOPHIL; BLAST CELL; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; EOSINOPHIL; FEMALE; HUMAN; LEUKOCYTE; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYDROXYUREA; INTERFERON ALFA-2B; LEUKEMIA, MYELOID, AGGRESSIVE-PHASE; MALE; MIDDLE AGED;

EID: 0029892236     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203859     Document Type: Article

References (26)

1. Silver RT, Gale RP: Chronic myeloid leukemia. Am J Med 1986;80:1137—1147.
2. Sokal JE, Baccarani M, Russo D, Tura S: Staging and prognosis in chronic myelogenous leukemia. Semin Haematol 1988;25(suppl 1):40-61.
3. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61:1441-1446.
4. Talpaz M, Kantarjian HM, Kurzrock R, Gut-terman J: Therapy of chronic myelogenous leukemia: Chemotherapy and interferons. Semin Hematol 1988;25:62-73.
5. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: Concise update. Blood 1993;82:691-703.
6. Thomas ED, Clift RA: Indications for marrow transplantation in chronic myelogenous leukemia. Blood 1989;73:861-864
7. Talpaz M, Kantarjian H, Kurzrock R, Gutter-man J: Update on therapeutic options for chronic myelogenous leukemia. Semin Hematol 1990;27(suppl 4): 31-36.
8. Higano CS, Raskin WH, Singer JW: Use of interferon-alpha-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation. Acta Haematol 1993;89(suppl 1):8-14.
9. Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG: Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 1987;14(suppl 2):29—35.
10. Ozcr H: Biotherapy of chronic myelogenous leukemia with interferon. Semin Oncol 1988; 15(suppl 5): 14-20.
11. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F: Interfcron-alpha-2b as therapy for patients with Ph-positive chronic myelogenous leukemia. Eur J Haematol 1990; 45(suppl 52):25—28.
12. Varbo JW: Mechanism of action of hydroxyurea Semin Oncol 1992; 19(suppl 9): 1 -10.
13. Hehlmann P, Heimpcl H, Hasford J: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 1993; 82:398-407.
14. Spiers ASD, Lorch CA, Harisson BA: Chronic granulocytic leukemia (CGL) in chronic phase with two Ph+ cell lines and suppression of one line by hydroxyurea (abstract 811). Blood 1986;(suppl l)68:233a.
15. Kolitz JE, Kempin SL, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gel T, Char-kon BD: A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin Oncol 1992;19(suppl 9):27—35.
16. Clift RA, Buckner CD: Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994;84:4368-4373.
17. Bullurini A, Keating A, Coldman J, Gale RP: Autotransplants in chronic myelogenous leukemia: Strategies and results. Lancet 1990;335: 1255-1258.
18. Barnett MJ, Eaves CS, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, Humbries RK, Klingemann HG, Nanterl SH, Recce DE, Shc-phcrcd JD, Spinclli JJ, Sutherland HJ, Eaves AC: Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study. Blood 1994:84:724-732.
19. Gomer GA, Sokal JE, Anngst CW: Chemotherapy of the terminal phase of chronic myelocytic leukemia with combinations of colchicine derivatives and purine analogs. Leukemia Res 1978;2:141-146.
20. Hayes DH, Ellison RR, Glidewell O, Holland JF, Silver RT: Chemotherapy for the terminal phase of chronic myelocytic leukemia. Cancer ChemotherRep 1974;4:233-247.
21. Foley HT, Bennett JM, Carbone PP: Combination chemotherapy in accelerated phase of chronic granulocytic leukemia. Arch Intern Med 1969;123:166-170.
22. Coleman M, Silver RT, Pajak T, Cavalli F, Rai KR, Kostinas JE, Glidewell O, Holland JF: Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and leukemia group B studies. Blood 1980;55: 29-36.
23. Saven A, Piro LD, Lemon RH, Figueroa ML, Kosky M, Ellison DJ, Beutler E: Complete hematologic remissions in chronic phase Philadelphia chromosome positive chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 1994;73:2953-2963.
24. Anger B, Porzsolt F, Lcichtle R, Hainze B, Bar-tam C, Heimpel H: A phase I/II study of recombinant interferon alpha-2b and hydroxyurea for chronic myelocytic leukemia. Blut 1989;58: 275-278.
25. Hehlmann R, Heimpel H, Hastford J: Randomized comparison of interferon-a with bu-sulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84:4064-4077.
26. Kolitz JE, Kempin SJ, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gee T, Clarkson BD: A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin Oncol 1992; 18(suppl):27—33.